Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


33. A.B. Csoka, G.I. Frost, and R. Stern, "The Six Hyaluronidase-like Genes in the Human and Mouse Genomes," Matrix Biol. 20 (8), 499–508 (2001).

34. Y. Lin et al., "A Hyaluronidase Activity of the Sperm Plasma Membrane Protein PH-20 Enables Sperm to Penetrate the Cumulus Cell Layer Surrounding the Egg," J. Cell. Biol. 125 (5), 1157–1163 (1994).

35. G.N. Cherr et al., "The PH-20 Protein in Cynomolgus Macaque Spermatozoa: Identification of Two Different Forms Exhibiting Hyaluronidase Activity," Dev. Biol. 175 (1), 142–153 (1996).

36. P. Gacesa, N.D. Civill, and R.A. Harrison, "PH-20 and Sperm Hyaluronidase: A Conceptual Conundrum in Mammalian Fertilization," Biochem. J. 303 (Pt. 1), 335–336 (1994).

37. G.I. Frost and R. Stern, "A Microtiter-based Assay for Hyaluronidase Activity not Requiring Specialized Reagents," Anal. Biochem. 251 (2), 263–269 (1997).

38. L.H. Bookbinder et al., "A Recombinant Human Enzyme for Enhanced Interstitial Transport of Therapeutics," J. Control Release 114 (2), 230–241 (2006).

39. H.D. Keiser and V.B. Hatcher, "The Effect of Contaminant Proteases in Testicular Hyaluronidase Preparations on the Immunologic Properties of Bovine Nasal Cartilage Proteoglycan," Connect Tissue Res. 6 (4), 229–233 (1979).

40. V.M. Doctor, H. Spence, and E.Y. Carroll, "Isolation and Properties of a New Anticoagulant Protein from Commercial Bovine Testicular Hyaluronidase," Thromb. Res. 30 (6), 565–571 (1983).

41. M. Hyuga, R. Kodama, and G. Eguchi, "Basic Fibroblast Growth Factor as One of the Essential Factors Regulating Lens Transdifferentiation of Pigmented Epithelial Cells," Int. J. Dev. Biol. 37 (2), 319–326 (1993).

42. J.C. Houck and C.M. Chang, "Permeability Factor Contaminating Hyaluronidase Preparations," Inflammation 3 (4), 447–451 (1979).

43. M. Oettl et al., "Comparative Characterization of Bovine Testicular Hyaluronidase and a Hyaluronate Lyase from Streptococcus agalactiae in Pharmaceutical Preparations," Eur. J. Pharm. 18 (3–4), 267–277 (2003).

44. M.F. Haller et al., "Escaping the Interstitial Matrix with Enzyme-Mediated Drug Delivery," Drug Delivery Technol. 5 (5), 40–45 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here